This article was originally published in The Gray Sheet
Premarket approval application supplement for NIR-On-Ranger coronary stent with Sox securement system is submitted to FDA July 28, the company says. The submission occurs nearly ten months after the firm voluntarily recalled the product on Oct. 5, 1998 due to higher than anticipated balloon failure rates (1"The Gray Sheet" Oct. 12, 1998, p. 28). Recall of the device commenced eight weeks after its launch
You may also be interested in...
Boston Scientific expects to generate $150-175 mil. U.S. stent revenue in the fourth quarter despite the firm's Oct. 5 voluntary recall of the NIR-On-Ranger coronary stent system with the SOX securing system.
Target guests in selected locations will be able to shop a curated Ulta Beauty section in the second half of 2021. The partnership could attract new clientele to Target stores and give Ulta a boost following nationwide store closures this year due to COVID.
COVID-19 Vaccines: ACIP’s Allocation Proposal Prioritizes Long-Term Care Residents, Essential Workers
First group to receive vaccine would comprise health care personnel and residents of long-term care facilities; next in line are non-health care essential workers, who would take priority over adults with high-risk medical conditions and those ages 65 years and older, according to the CDC advisory committee’s proposed allocation framework.